Cardiologia Croatica, Vol. 15 No. 3-4, 2020.
Stručni rad
https://doi.org/10.15836/ccar2020.75
Non-Interventional Study of Efficacy and Safety of Rosuvastatin Therapy and Introduction of Additional Doses to Clinical Practice in Patients with Hyperlipidemia
Borut Jug
; Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija
Breda Barbič-Žagar
; Krka, d. d., Novo mesto, Slovenija
Mateja Grošelj
; Krka, d. d., Novo mesto, Slovenija
Darja Milovanović Jarh
; Krka, d. d., Novo mesto, Slovenija
Tjaša Lipušček
; Krka, d. d., Novo mesto, Slovenija
Sažetak
Cardiovascular (CV) diseases remain the leading cause of morbidity and mortality in the world and in Slovenia. According to the recommendations of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, reducing LDL-cholesterol levels, especially with statins, is essential for prevention of CV events. A number of clinical studies and years of experience demonstrate the efficacy of statin therapy. Nevertheless, they are still rarely used in clinical practice or are used at insufficient doses. The clinical efficacy of all doses of Krka’s rosuvastatin (Roswera®) was monitored in FROZEN, a three-month non-interventional study. The results showed that patients at high or very high risk of a cardiovascular event were undertreated and were less likely to reach target LDL-C levels than moderate-risk patients. Treatment was evaluated as safe and effective during the follow-up period in patients at a moderate, high, and very high CV risk.
Ključne riječi
rosuvastatin; hyperlipidemia; low-density lipoprotein cholesterol; efficacy; safety
Hrčak ID:
236322
URI
Datum izdavanja:
26.3.2020.
Posjeta: 1.347 *